يعرض 1 - 10 نتائج من 160 نتيجة بحث عن '"ER-breast cancer"', وقت الاستعلام: 0.83s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية

    المساهمون: NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), Centro de Estudos de Doenças Crónicas (CEDOC), iNOVA4Health - pólo NMS, Instituto de Tecnologia Química e Biológica António Xavier (ITQB), DCV - Departamento de Ciências da Vida, UCIBIO - Applied Molecular Biosciences Unit

    العلاقة: PURE: 33310345; PURE UUID: dfdc825e-1538-4c9d-9c62-37ceff9b5ee9; Scopus: 85112348312; PubMed: 34439228; PubMedCentral: PMC8392387; ORCID: /0000-0001-5987-2485/work/100976789; ORCID: /0000-0001-8867-2407/work/123561666; WOS: 000689049500001; http://hdl.handle.net/10362/147438Test; https://doi.org/10.3390/cancers13164074Test

  8. 8
    دورية أكاديمية
  9. 9
    دورية أكاديمية
  10. 10

    المساهمون: Gonzalez-Perez, Abel [0000-0002-8582-4660], Oliveira, Mafalda [0000-0001-9152-8799], Ibrahimi, Nusaibah [0000-0003-4537-0323], Kannan, Srinivasaraghavan [0000-0002-9539-5249], Sánchez-Guixé, Mònica [0000-0002-9430-4413], Hernández, Javier [0000-0003-1526-3201], Clarke, Robert B [0000-0001-5407-3123], Caldas, Carlos [0000-0003-3547-1489], Arribas, Joaquín [0000-0002-0504-0664], Michiels, Stefan [0000-0002-6963-2968], Turner, Nicholas C [0000-0001-8937-0873], Prat, Aleix [0000-0003-2377-540X], Nuciforo, Paolo [0000-0003-1380-0990], Lopez-Bigas, Nuria [0000-0003-4925-8988], Scaltriti, Maurizio [0000-0002-5522-1447], Saura, Cristina [0000-0001-8296-5065], Serra, Violeta [0000-0001-6620-1065], Apollo - University of Cambridge Repository, Institut Català de la Salut, [Palafox M, Monserrat L, Òdena A, Sánchez-Guixé M, Rodríguez O, Guzmán M, Grueso J] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Bellet M, Bellet M, Capelán M, Azaro A, Saura C] Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Villacampa G, Viaplana C, Dienstmann R] Oncology Data Science Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Gonzalez-Perez A] Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain. Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain. [Hernández J] Grup de Recerca de Patologia Molecular Translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Arribas J] CIBERONC, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Growth Factors Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. [Nuciforo P] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Serra V] Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. CIBERONC, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Clarke, R 2022, ' High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer. ', Nature Communications, vol. 13, no. 1, 5258 . https://doi.org/10.1038/s41467-022-32828-6Test
    Scientia

    مصطلحات موضوعية: endocrine system, Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Neoplasm [PHENOMENA AND PROCESSES], endocrine system diseases, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Ubiquitin-Protein Ligases, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], General Physics and Astronomy, Antineoplastic Agents, Breast Neoplasms, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Predictive markers, Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors [CHEMICALS AND DRUGS], General Biochemistry, Genetics and Molecular Biology, Càncer de mama, Phosphatidylinositol 3-Kinases, Text mining, Breast cancer, Er breast cancer, Medicine, Humans, Cancer models, neoplasms, Protein Kinase Inhibitors, Resistència als medicaments, fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos::resistencia a los antineoplásicos [FENÓMENOS Y PROCESOS], neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Multidisciplinary, Manchester Cancer Research Centre, acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas [COMPUESTOS QUÍMICOS Y DROGAS], business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Inhibitor resistance, Cyclin-Dependent Kinase 4, General Chemistry, Cyclin-Dependent Kinase 6, Proteïnes quinases - Inhibidors, Retinoblastoma Binding Proteins, Receptors, Estrogen, Drug Resistance, Neoplasm, Drug resistance, Mama - Càncer - Tractament, Cancer research, Female, business, Biomarkers

    وصف الملف: application/pdf